China Medical System (CHSYF) announced that its subsidiary, Dermavon Holdings has obtained the relevant licensing rights to the oral JAK1 inhibitor povorcitinib, which has been included in the list of Breakthrough Therapeutic Drugs by the Center for Drug Evaluation of the National Medical Products Administration of the People’s Republic of China, with a proposed indication for adult patients with non-segmental vitiligo. This certification has the potential to accelerate the development and review process of the Product.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CHSYF:
- China Medical System’s Breakthrough in Vitiligo Treatment with Povorcitinib
- China Medical System announces NMPA acceptance of Y-3 NDA
- China Medical System’s Innovative Stroke Treatment Gains Regulatory Acceptance
- China Medical System Holdings Maintains Stable Share Capital in November 2025
- China Medical System announces NMPA acceptance of MG-K10 NDA